Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Y's Therapeutics Co. Ltd.

www.ysthera.com

Latest From Y's Therapeutics Co. Ltd.

Y's confident in lead project after new data

The private Japanese venture Y's Therapeuticshas been buoyed by more positive news for its development pipeline, this time in the form of promising early Phase II results for its lead project, YSPSL.

Cardiovascular Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Y's Therapeutics Co. Ltd.
  • Senior Management
  • Masanori Murayama, Pres. & CEO
    Ryuta Fujikawa, VP, CFO
    Teikichi Aoyagi, PhD, VP, Clinical Dev. & COO
  • Contact Info
  • Y's Therapeutics Co. Ltd.
    Phone: (81) 357842762
    1-10-11 Ebisu-Nishi, Fujiwara Bldg. 5F
    Tokyo, 105-0001
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register